Cyclazocine |
 |
|
Routes of administration | By mouth |
|---|
| ATC code | |
|---|
|
3-(Cyclopropylmethyl)-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol or 2-Cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| IUPHAR/BPS | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.020.627 |
|---|
|
| Formula | C18H25NO |
|---|
| Molar mass | 271.404 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
Oc1ccc4c(c1)C2(C(C(N(CC2)CC3CC3)C4)C)C
|
InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3 YKey:YQYVFVRQLZMJKJ-UHFFFAOYSA-N Y
|
N Y (what is this?) (verify) |
Cyclazocine is a mixed opioid agonist/antagonist related to dezocine, pentazocine and phenazocine. It is in the benzomorphan and benzazocine family of drugs.[1] It is a κ-opioid receptor agonist and μ-opioid receptor partial agonist, and also has high affinity for the δ-opioid receptor.[2]
Research
Research into the use of cyclazocine for the treatment of bipolar patients with depression was undertaken by Fink and colleagues (1970). It showed that 8 out of 10 patients experienced moderate improvement.
Research during the 1960s and 1970s into the possible use of cyclazocine for management of pain, and later for assisting treatment of opioid addiction was severely hampered by the drug's psychotomimetic, dysphoric, and hallucinatory effects.[3] The dysphoric/anxiety-inducing effects of the drug correlate with increasing dosage and would likely reduce the risk of abuse in the same manner as other opioids which preferentially act on the KOR versus the DOR and MOR, although the side-effect threshold is often lower than the lowest effective dose.
References
- ^ Archer S, Glick SD, Bidlack JM (November 1996). "Cyclazocine revisited". Neurochemical Research. 21 (11): 1369–1373. doi:10.1007/BF02532378. PMID 8947927. S2CID 680860.
- ^ Bidlack JM, Cohen DJ, McLaughlin JP, Lou R, Ye Y, Wentland MP (July 2002). "8-Carboxamidocyclazocine: a long-acting, novel benzomorphan". The Journal of Pharmacology and Experimental Therapeutics. 302 (1): 374–380. doi:10.1124/jpet.302.1.374. PMID 12065740. S2CID 15864569.
- ^ Freedman AM, Fink M, Sharoff R, Zaks A (October 1967). "Cyclazocine and methadone in narcotic addiction". JAMA. 202 (3): 191–194. doi:10.1001/jama.1967.03130160065011. PMID 6072354.
Analgesics (N02A, N02B) |
|---|
| Opioids | | Opiates/opium | |
|---|
| Semisynthetic | |
|---|
| Synthetic | |
|---|
|
|---|
| Paracetamol-type | |
|---|
| NSAIDs | |
|---|
| Cannabinoids | |
|---|
Ion channel modulators | | Calcium blockers | |
|---|
| Sodium blockers |
- Nav1.7/1.8-selective: DSP-2230§
- Funapide§
- PF-05089771§
- Suzetrigine
|
|---|
| Potassium openers | |
|---|
|
|---|
| Myorelaxants | |
|---|
| Others | |
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
Hallucinogens |
|---|
Psychedelics (5-HT2A agonists) |
- Tryptamines (e.g., DMT, psilocin, psilocybin, bufotenin, 5-MeO-DMT, AMT)
- Phenethylamines (e.g., mescaline, 2C-B, DOM, MDA, TMA, 2C-B-FLY, 25I-NBOMe)
- Lysergamides (e.g., LSD, ergine, isoergine)
- Others (e.g., efavirenz, IHCH-7113, MK-212, quipazine, RH-34)
- For a full list of serotonergic psychedelics, see the navbox here and the list here instead.
|
|---|
Dissociatives (NMDA antagonists) |
- Arylcyclohexylamines (e.g., ketamine (K), phencyclidine (PCP), methoxetamine (MXE), tiletamine)
- Adamantanes (e.g., memantine, amantadine)
- Diarylethylamines (e.g., diphenidine, ephenidine, methoxphenidine)
- Morphinans (e.g., dextromethorphan (DXM), dextrorphan (DXO))
- Inhalants (e.g., nitrous oxide (N2O), xenon (Xe))
- Others (e.g., alkyl nitrites/poppers, aptiganel, dexoxadrol, dizocilpine (MK-801), etoxadrol, selfotel)
- For a full list of dissociatives, see the navbox here instead.
|
|---|
Deliriants (mACh antagonists) | |
|---|
| KOR agonists |
- Salvinoids (terpenoids): 2-EMSB
- 2-MMSB
- RB-64 (22-thiocyanatosalvinorin A)
- Salvinorin A
- Arylacetamides: Enadoline
- LPK-26
- Niravoline
- Spiradoline
- U-50488
- U-69593
|
|---|
| GABAA agonists |
- Indirect GABAA receptor agonists: GABAA receptor positive allosteric modulators (nonbenzodiazepines/Z-drugs) (e.g., eszopiclone, zaleplon, zolpidem, zopiclone)
- GABA reuptake inhibitors (e.g., CI-966)
|
|---|
Oneirogens (unknown mech.) |
- Harmala alkaloids/β-carbolines (e.g., harmine, harmaline, tetrahydroharmine, 6-methoxyharmalan, 6-MeO-THH) (found in Peganum harmala, Banisteriopsis caapi)
- Iboga alkaloids/azepinoindoles (e.g., ibogaine, noribogaine) (found in Tabernanthe iboga)
|
|---|
Cannabinoids (CB1 agonists) |
- For a full list of cannabinoids, see the navbox here and the list here instead.
|
|---|
| Others |
- Aminochromes (e.g., adrenochrome, adrenolutin)
- Carbogen
- Glaucine
- Hallucinogenic bolete mushrooms (e.g., Lanmaoa asiatica)
- Jenkem
- Kykeon (Eleusinian Mysteries)
- Nutmeg (e.g., myristicin, elemicin)
- Soma (haoma)
|
|---|
- See also: Psychedelics
- Dissociatives
- Entactogens
- Stimulants
- Depressants
- List of hallucinogens
|
Sigma receptor modulators |
|---|
| σ1 |
- Allosteric modulators: Phenytoin; Positive: Methylphenylpiracetam
- SOMCL-668
|
|---|
| σ2 |
- Antagonists: AC-927
- BD-1008
- BD-1067
- CM-156
- LR-172
- MIN-101
- Panamesine (EMD-57455)
- SAS-0132
- Zervimesine (CT-1812)
- Unknown/unsorted: 3-Methoxydextrallorphan
- 3-MeO-PCE
- 4-MeO-PCP
- 5-MeO-DALT
- 5-MeO-DiPT
- Clemastine
- DiPTTooltip N,N-Diisopropyltryptamine
- DPTTooltip N,N-Dipropyltryptamine
- Ibogaine
- Lu 29-252
- Nemonapride
- Nepinalone
- Noribogaine
- Pentazocine
- RS-67,333
- Safinamide
- TMATooltip 3,4,5-Trimethoxyamphetamine
- UMB-23
- UMB-82
- W-18
|
|---|
| Unsorted |
- Antagonists: AHD1
- AZ66
- Lamotrigine
- Naloxone
- SM-21
- UMB-100
- UMB-101
- UMB-103
- UMB-116
- YZ-011
- YZ-069
- YZ-185
- Allosteric modulators: SKF-83959
|
|---|
See also: Receptor/signaling modulators |